XML 208 R162.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Liabilities related to business combinations and to non-controlling interests - Additional Information (Details) - EUR (€) € in Millions | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
--- | --- | --- | --- | ---
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Fair value of contingent consideration payable | € 709 | € 779 | € 714 | € 605
Commitments relating to contingent consideration in connection with business combinations | € 133 | 604 | 689 |
MSD contingent consideration (European vaccines business) |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Increase in fair value of liability | 1.00% |  |  |
Fair value of contingent consideration payable | € 127 | 204 | 269 | 312
Shire contingent consideration arising from the acquisition of Translate Bio |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Fair value of contingent consideration payable | € 441 | 380 | 354 | 0
Shire contingent consideration |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Increase in fair value of liability | 12.00% |  |  |
Amunix |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |
Increase in fair value of liability | 1.00% |  |  |
Fair value of contingent consideration payable | € 137 | € 165 | € 0 | € 0

X
- Definition The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2023-01-01 -Paragraph B67 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Relating To Contingent Consideration In Connection With Business Combinations + References No definition available. + Details
Name: | sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] + References No definition available. + Details
Name: | sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage increase in fair value liabilities. + References No definition available. + Details
Name: | sny_PercentageIncreaseInFairValueLiabilities
Namespace Prefix: | sny_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ShireHumanGeneticTherapiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_AmunixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |